Trial 1 – Proven effectiveness of Clarymist ™
Stringent Methodology
A study of 382 dry eye sufferers was performed in Stuttgart between August 2003 and May 2004 to test the effectiveness of Clarymist ™ eye spray – at that time marketed in Germany as Tears Again TM. The methodology for the trial was exceptionally stringent, being 'double blind', which means that neither the clinicians nor the volunteer users knew who was taking the real product and who was taking a placebo control. These precautions eliminate the common experimental errors of observer and subject bias, and assure highly reliable findings.
Clearly Demonstrated Effectiveness
At the end of the trial, parameters such as LIPCOF, BUT, and Schirmer were all significantly superior in the treatment group compared to the control group. Other effects included a remarkable reduction of 89.5% in inflammation of the margins of the eyelid. Questioning of the patients revealed a subjective perception of reduced symptoms in 72% of the cases. Also every patient was of the opinion that using Clarymist ™ eye spray is more straightforward and more pleasant than tear substitute eye drops.
Reference
These outstanding results achieved were published in the leading German Ophthalmic Journal. (Klin Monatsbl Augenheilkunde 2004;221: 825-836)
Trial 2 – Comparative trial demonstrates efficacy and usability
Positive comparison with eye gel
A further blinded crossover study compared Clarymist ™ eye spray with a triglyceride gel treatment that also addresses the tear film lipid phase. Parameters measured were almost identical to the first study.
The conclusions state that Clarymist ™ eye spray showed statistically significant clinical advantages over the triglyceride tear substitute on all the key measurements. In addition, 96% of the patients stated that they preferred the Clarymist ™ eye spray method of application to the gel system.
Reference
'Comparative study of the therapy of dry eye syndrome with artificial tear substitutes especially for the treatment of the disturbance of the lipid layer.’ Lee S., Dausch D., Dausch S. Klinikum St. Marien, Amberg
Trial 3 – Clarymist outperforms Liposic
A randomised, controlled, multicenter crossover study included 74 patients demonstrated the superiority of Clarymist™ in comparison to another common lipid based treatment, Liposic. All measured parameters were shown to be superior in the Clarymist group, both before and after cross over.
This backs up previous data that suggests the unique liposomal phospholipids nature of Clarymist™ is a more suitable treatment than non-polar lipids.
Reference
Comparative study of treatment of the dry eye syndrome due to disturbances of the tear film lipid layer with lipid-containing tear substitutes
Efficacy of lipid-containing tear substitutes
Dausch D., Lee S.,, Dausch S., Kim J.C., Schwert G., Michelson W.
Please Note:
This product has been rebranded for the UK and Ireland and is called Clarymist TM.
